Safety of bevacizumab in mild haemophilia B.
Lambert
Catherine
C
Haemostasis and Thrombosis Unit, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.
Deneys
Véronique
V
Pothen
Dominique
D
Hermans
Cedric
C
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002836:Hemophilia B / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab